导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.91% | 1989/4773 |
| 近一周 | -2.10% | 1235/5462 |
| 近一月 | -6.07% | 3438/5421 |
| 近一季 | -10.47% | 3498/5209 |
| 近半年 | -8.48% | 3349/4920 |
| 近一年 | 9.40% | 1096/4366 |
| 近两年 | 82.58% | 774/2954 |
| 近三年 | 49.31% | 547/2253 |
| 成立以来 | 161.02% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.07% 592/4961 |
12.01% 2252/5312 |
- - |
- - |
| 2025 | 42.58% 697/4813 |
3.63% 1061/3635 |
3.53% 997/4076 |
26.88% 1326/4524 |
4.74% 494/4813 |
| 2024 | 5.22% 1844/3463 |
-5.93% 1978/2808 |
-2.17% 1146/3014 |
13.01% 2261/3129 |
1.17% 1112/3463 |
| 2023 | 3.72% 265/2656 |
10.33% 374/2280 |
-3.39% 786/2385 |
-1.18% 488/2515 |
-1.54% 339/2655 |
| 2022 | -18.90% 771/2207 |
-12.26% 596/1919 |
6.05% 779/2016 |
-12.97% 812/2113 |
0.15% 1533/2208 |
| 2021 | 26.09% 102/1822 |
2.96% 204/1255 |
16.62% 197/1330 |
5.16% 289/1466 |
-0.15% 1206/1822 |
| 2020 | 29.88% 529/1250 |
-5.23% 405/1028 |
20.60% 267/1067 |
11.99% 411/1164 |
1.48% 1027/1184 |
| 2019 | - - |
- - |
- - |
1.32% 413/850 |
8.76% 293/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 长城中证500指数增强C VS. 长安沪深300非周期A(740101) |